My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

42.63 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 Next >

Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

November 29, 2022

Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.

Via Investor's Business Daily

Where Xenon Pharmaceuticals Stands With Analysts ↗

November 28, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022 ↗

November 28, 2022

Via Benzinga

Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗

November 09, 2022

Biotech stocks were hammered Wednesday, including several that had good news.

Via Investor's Business Daily

Earnings Scheduled For November 8, 2022 ↗

November 08, 2022

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

Via Benzinga

Analyst Sees This Epilepsy Player As 'M&A Sweet Spot' ↗

October 19, 2022

Via Benzinga

Earnings Preview: Xenon Pharmaceuticals ↗

November 07, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Xenon...

Via Benzinga

Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends. ↗

November 01, 2022

As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends.

Via InvestorPlace

Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗

September 04, 2022

The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.

Via Talk Markets

Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says ↗

August 29, 2022

Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 ↗

August 29, 2022

Upgrades

Via Benzinga

Analyst Ratings for Xenon Pharmaceuticals ↗

August 29, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022 ↗

October 19, 2022

Upgrades

Via Benzinga

4 Analysts Have This to Say About Xenon Pharmaceuticals ↗

October 11, 2022

Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:

Via Benzinga

4 Analysts Have This to Say About Xenon Pharmaceuticals ↗

August 11, 2022

Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:

Via Benzinga

What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals ↗

August 11, 2022

Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter:

Via Benzinga

Xenon Pharmaceuticals: Q2 Earnings Insights ↗

August 09, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For Xenon Pharmaceuticals ↗

August 08, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.

Via Benzinga

The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise ↗

June 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency ↗

June 23, 2022

Via Benzinga

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering ↗

June 22, 2022

Via Benzinga

Recap: Xenon Pharmaceuticals Q1 Earnings ↗

May 10, 2022

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For August 9, 2022 ↗

August 09, 2022

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022 ↗

July 21, 2022

Upgrades

Via Benzinga

Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All ↗

June 23, 2022

The company had bullish results in seizure treatment. But it wasn't enough.

Via Investor's Business Daily

US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony ↗

June 23, 2022

Pre-open movers

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Looking Into Xenon Pharmaceuticals's Return On Capital Employed ↗

June 13, 2022

According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67...

Via Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For May 10, 2022 ↗

May 10, 2022

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.